A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №2, 2026

more

A.I. Burnasyan  FMBC clinical bulletin. 2026 № 2

Y.D. Udalov1, Yu.S. Kitaeva2, B.G. Jurgin1, O.V. Parinov1

Development of Metabolic Disorders During Pathogenetic Therapy for Hemoblastoses.
A Comparative Analysis of Clinical Cases

1International Office, State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russiа

2Russian National Research Medical University named after. N. I. Pirogova,  Moscow, Russia

Contact person: Kitaeva Julya Sergeevna: jkhema@yandex.ru

 

Abstract
Metabolic disorders that occur in patients with leukemia after undergoing pathogenetic therapy and bone marrow transplantation are a relevant problem that is often underestimated due to the lack of clear clinical symptoms. Antitumor treatment disrupts metabolic processes in the body, requiring timely diagnosis at each stage of therapy. This article presents two clinical cases of female patients with leukemia who underwent polychemotherapy. The patients’ BMI, biochemical parameters, lipid profile, and hormonal status were evaluated. At the onset, both patients did not have pronounced metabolic abnormalities. After treatment, the first patient had high cholesterol levels and severe obesity, while the second patient had moderate hyperlipidemia but significant weight loss. These cases demonstrate different outcomes with the same treatment regimen, highlighting the importance of a personalized approach to patients.

Keywords: metabolic syndrome, dyslipidemia, leukemia, hematology, chemotherapy, bone marrow transplantation

For citation: Udalov YD, Kitaeva YuS, Jurgin BG, Parinov OV. Development of Metabolic Disorders During Pathogenetic Therapy for Hemoblastoses. A Comparative Analysis of Clinical Cases. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2026.2:113-116. (In Russian) DOI: 10.33266/2782-6430-2026-2-113-116

 

REFERENCES

  1. Saklayen M.G. The Global Epidemic of the Metabolic Syndrome. Current Hypertension Reports. 2018;20;2:12.
  2. Назарова М.И., Серербровская Т.В., Карпова О.В. Метаболический синдром: диагностические критерии и современные подходы к лечению // Терапевтический архив. Т.91. №12. С. 45–53 [Nazarova M.I., Sererbrovskaya T.V., Karpova O.V. Metabolic Syndrome: Diagnostic Criteria and Modern Approaches to Treatment. Terapevticheskiy Arkhiv = Therapeutic Archive. 2019;91;12:45–53 (In Russ.)].
  3.  Monteiro R., Azevedo I., Calhau C. Metabolic Syndrome, Inflammation and Cancer: the Role of Adipokines and Cytokines. Inflammation Research. 2019;68;7:541–552.
  4.  Anderson M.A., Johnson E.C., Williams C.D. The Interplay between Metabolic Syndrome and Hematologic Malignancies: a Review. Blood Reviews. 2021;48:100795.
  5. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2020. CA. A Cancer Journal for Clinicians. 2020;70;1:7–30.6. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2020. CA: a Cancer Journal for Clinicians. 2020;70;1:7–30.
  6. Malard F., Mohty M. New Insights into the Understanding of Immune Responses after Allogeneic Hematopoietic Stem Cell Transplantation. Bone Marrow Transplantation. 2020;55;4:711–722.
  7. Malard F., Mohty M. New Insights into the Management of Acute Graft-Versus-Host Disease. Blood.2020;135;9:687–694.
  8. Karim E., et al. Hepatoprotective and Lipid-Lowering Strategies in Patients under Immunosuppressive Regimens: a Systematic Review. Transplant Rev (Orlando). 2021;35;2: 100579.
  9. Froehlich G. M., et al. Obesity and Ventricular Arrhythmias: a Meta-Analysis of Adiposity and Ventricular Tachyarrhythmias. Obesity Reviews. 2019;20;6:865–868.
  10. Froehlich E.V., et al. Glucocorticoid-Induced Metabolic Complications in Hematologic Malignancies: a Clinical Overview. Blood Rev. 2019;37:100584.
  11. Wang Y., et al. Microbial Modulation of Immunosuppressive Treatments in Allogeneic Hematopoietic Stem Cell Transplantation. Cell Host Microbe. 2021;29;5:755–767.
  12. Grignoli E., et al. Corticosteroid Therapy in Chronic Hematological Disorders: Balancing Efficacy and Metabolic Side Effects. Leukemia Research. 2022;117:106893.
  13. Chung T., et al. Inflammatory Markers and Cachexia in Leukemia Patients: a Prospective Analysis. Clin Nutr. 2022;41;3:672–680.
  14. Hashimoto S., et al. Genetic Predisposition to Steroid Response in Hematologic Cancers. Haematologica, 2019;104;9:1778–1788.
  15. Chang J., et al. Thyroid Dysfunction and Hyperlipidemia in Patients with Chronic Leukemia Receiving Chemo- and Targeted Therapy. Thyroid, 2019;29;11:1537–1545.
  16. Hashimoto S., et al. Genetic Predisposition to Steroid Response in Hematologic Cancers. Haematologica. 2019;104;9:1778–1788.
  17. Park S., et al. Multidisciplinary Approach to Metabolic Syndrome in Hematopoietic Stem Cell Transplantation Survivors. Transplant Cell Ther. 2021;27;9:777.e1–777.e7.
  18. Sakamoto K., et al. Subclinical Hypothyroidism in Leukemia Patients: does Levothyroxine Improve Outcomes? Endocr Pract. 2018;24;8:765–772.
  19. Przepiorka D., et al. Guidelines for Personalized Conditioning Regimens in Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2021;56;9:2200–2209.
  20. Mashhadi M.A., et al. Nutritional Intervention and Mortality in Hematologic Cancer Patients Receiving Chemotherapy: a Meta-Analysis. Nutrition. 2020;74:110751.
  21. Jia W., et al. Gut Microbiome and Anticancer Therapy-Related Toxicity. Cancer Lett. 2020; 482:50–57.
  22. Chang J., et al. Thyroid Dysfunction and Hyperlipidemia in Patients with Chronic Leukemia Receiving Chemo- and Targeted Therapy. Thyroid. 2019;29;11:1537–1545.
  23. NCCN Guidelines. Management of Immunosuppressive Agents in Hematologic Malignancies, version 3.2023. National Comprehensive Cancer Network, 2023.

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 03.052026. Accepted for publication: 22.05.2026

© 2026 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top